China NMPA Product Recall - Atellica HEMA Diluent for Blood Cell Analysis

Siemens Healthcare Diagnostics Inc. has initiated a voluntary Class III recall for its Atellica HEMA Diluent for Hematology Analysis, as reported by Siemens Healthcare Diagnostics Products (Shanghai) Co., Ltd., and publicly announced by the National Medical Products Administration (NMPA) on September 7, 2022. The recall addresses a critical product issue where the container handle, on specific models and batches, may unexpectedly break when the product is lifted. This defect could potentially compromise user safety and product integrity during handling within clinical and laboratory settings. This proactive measure, classified as a Class III recall, indicates that while the issue is important, it is unlikely to cause serious adverse health consequences. However, it mandates corrective action to prevent potential user injury or inconvenience. The regulatory framework for this recall is established by the NMPA, which oversees medical device safety and quality in China. Siemens Healthcare Diagnostics Inc. is committed to ensuring compliance and mitigating risks associated with its products. Required actions include the identification and return of affected units, with comprehensive details provided in the official Medical Device Recall Event Report Form to facilitate a safe and efficient recall process. The company's swift response underscores its dedication to patient and user safety.